# 2025-16267: NEMLUVIO's Patent Extension: FDA Times It Just Right

2025-16267, Determination of Regulatory Review Period for Purposes of Patent Extension; NEMLUVIO, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-08-26 (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2025-16267
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-16267
- Title: Determination of Regulatory Review Period for Purposes of Patent Extension; NEMLUVIO
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 41581
- Published: 2025-08-26
- Effective: unknown
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

NEMLUVIO's Patent Extension: FDA Times It Just Right

## Summary

The FDA has officially set the review period for NEMLUVIO, a human biological product, so its patent can be extended. This means the company behind NEMLUVIO gets extra time to protect their invention and keep making money. Anyone interested in drug patents or new medicines should watch this space for timing and legal updates.

## Abstract

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for NEMLUVIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.

## Effects PRIA read

- Patent Extension OK for NEMLUVIO: benefit, medium. The FDA has determined the regulatory review period for NEMLUVIO so the patent on that human biological product can be extended. This gives the company behind NEMLUVIO extra time to protect its invention and continue earning revenue from the product.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-16267 on federalregister.gov](https://www.federalregister.gov/documents/2025/08/26/2025-16267/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nemluvio)
- [2025-16267 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-08-26/pdf/2025-16267.pdf)

## Related
- [Previous: 2025-16266, Determination of Regulatory Review Period for Purposes of Patent Extension; LUM…](https://policyrisk.com/federal-register/2025-16266)
- [Next: 2025-16268, Agency Information Collection Activities; Submission for Office of Management a…](https://policyrisk.com/federal-register/2025-16268)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-16267 (as of 2026-06-08).
